Articles with public access mandates - Alexa SchrockLearn more
Available somewhere: 48
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
Genome medicine 9, 1-14, 2017
Mandates: US Department of Defense
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Mandates: US National Institutes of Health, V Foundation, USA
Acquired Resistance to KRASG12C Inhibition in Cancer
MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ...
New England Journal of Medicine 384 (25), 2382-2393, 2021
Mandates: US National Institutes of Health, Doris Duke Charitable Foundation …
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ...
Journal of Clinical Oncology 35 (23), 2624-2630, 2017
Mandates: US National Institutes of Health
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
JJ Lin, VW Zhu, S Yoda, BY Yeap, AB Schrock, I Dagogo-Jack, NA Jessop, ...
Journal of Clinical Oncology 36 (12), 1199-1206, 2018
Mandates: US National Institutes of Health
Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers
AD Singhi, B George, JR Greenbowe, J Chung, J Suh, A Maitra, ...
Gastroenterology 156 (8), 2242-2253. e4, 2019
Mandates: Pancreatic Cancer Action Network, USA
Structure-based classification predicts drug response in EGFR-mutant NSCLC
JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ...
Nature 597 (7878), 732-737, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
Mandates: Government of Italy
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ...
Journal of gastrointestinal oncology 9 (4), 610, 2018
Mandates: US National Institutes of Health
Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC
JW Riess, DR Gandara, GM Frampton, R Madison, N Peled, JA Bufill, ...
Journal of Thoracic Oncology 13 (10), 1560-1568, 2018
Mandates: US National Institutes of Health
Genomic profiling of small-bowel adenocarcinoma
AB Schrock, CE Devoe, R McWilliams, J Sun, T Aparicio, PJ Stephens, ...
JAMA oncology 3 (11), 1546-1553, 2017
Mandates: Cancer Research UK
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
AP Garner, JM Gozgit, R Anjum, S Vodala, A Schrock, T Zhou, C Serrano, ...
Clinical Cancer Research 20 (22), 5745-5755, 2014
Mandates: US National Institutes of Health
Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity
JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ...
Cancer Cell 36 (4), 444-457. e7, 2019
Mandates: US Department of Defense, US National Institutes of Health
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In …
SM Ali, T Hensing, AB Schrock, J Allen, E Sanford, K Gowen, A Kulkarni, ...
The oncologist 21 (6), 762-770, 2016
Mandates: US National Institutes of Health
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
SB Maron, L Alpert, HA Kwak, S Lomnicki, L Chase, D Xu, E O'Day, ...
Cancer discovery 8 (6), 696-713, 2018
Mandates: US National Institutes of Health
ROS1 fusions rarely overlap with other oncogenic drivers in non–small cell lung cancer
JJ Lin, LL Ritterhouse, SM Ali, M Bailey, AB Schrock, JF Gainor, LA Ferris, ...
Journal of Thoracic Oncology 12 (5), 872-877, 2017
Mandates: US National Institutes of Health
RET rearrangements are actionable alterations in breast cancer
BS Paratala, JH Chung, CB Williams, B Yilmazel, W Petrosky, K Williams, ...
Nature communications 9 (1), 4821, 2018
Mandates: US National Institutes of Health
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, F Morano, G Fucà, ...
Annals of Oncology 29 (6), 1394-1401, 2018
Mandates: Government of Italy
On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation
BP Brown, YK Zhang, D Westover, Y Yan, H Qiao, V Huang, Z Du, ...
Clinical Cancer Research 25 (11), 3341-3351, 2019
Mandates: US National Institutes of Health, V Foundation, USA, Damon Runyon Cancer …
HER2 transmembrane domain (TMD) mutations (V659/G660) that stabilize homo-and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib
SHI Ou, AB Schrock, EV Bocharov, SJ Klempner, CK Haddad, ...
Journal of Thoracic Oncology 12 (3), 446-457, 2017
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program